Article | March 8, 2018

Are Today's Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?

Source: GE Healthcare Life Sciences

Dr. Mats Lundgren, Customer Applications Director, GE Healthcare Life Sciences

Are Today’s Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?

While vaccines are critical to the survival of many patient populations, especially children, they were previously considered low-revenue products, generating limited interest in the market. Consequently, North America has seen a significant decline in the number of vaccine manufacturers over the years. Nevertheless, new trends are changing the vaccine market, and viral vector-based vaccines and other therapies are becoming essential to the treatment of many diseases, sparking new interest across the industry. Even the groundbreaking area of cell and gene therapy is seeing the application of viral vectors as a platform for vaccines and therapeutic applications. As a shift toward high-value, low-volume vaccines and viral vector-based therapies continues, it is important to recognize the limitations of today’s production processes in order to overcome the challenges, complexity, and high cost of manufacturing these drugs.